Repurposing the SSRI paroxetine increases lymphocyte mobilization and improves the efficacy of measles virus-based immunovirotherapy.
1/5 보강
Glioblastoma (GBM) is the most common primary malignant brain tumor, with a poor prognosis and limited response to immunotherapy.
APA
Stergiopoulos GM, Concilio SC, et al. (2026). Repurposing the SSRI paroxetine increases lymphocyte mobilization and improves the efficacy of measles virus-based immunovirotherapy.. Molecular therapy. Oncology, 34(1), 201109. https://doi.org/10.1016/j.omton.2025.201109
MLA
Stergiopoulos GM, et al.. "Repurposing the SSRI paroxetine increases lymphocyte mobilization and improves the efficacy of measles virus-based immunovirotherapy.." Molecular therapy. Oncology, vol. 34, no. 1, 2026, pp. 201109.
PMID
41542034 ↗
Abstract 한글 요약
Glioblastoma (GBM) is the most common primary malignant brain tumor, with a poor prognosis and limited response to immunotherapy. Systemic immunosuppression in GBM is a significant challenge partly driven by T cell sequestration in the bone marrow via sphingosine-1-phosphate receptor 1 (S1P1) internalization by G protein-coupled receptor kinase 2 (GRK-2). We demonstrated that immunovirotherapy based on oncolytic measles virus armed with the neutrophil-activating protein (MV-s-NAP), combined with anti-PD-1 and anti-TIGIT, increases S1P1 expression on bone marrow lymphocytes. Furthermore, repurposing paroxetine, one of the Food and Drug Administration-approved selective serotonin reuptake inhibitors (SSRIs) with GRK-2 inhibitory action, enhanced this effect, leading to greater lymphocyte circulation, activation, and improved survival in an orthotopic syngeneic mouse model. By overcoming key mechanisms of immune suppression and repurposing a widely available, clinically safe drug, this strategy represents a highly translatable approach to enhancing the efficacy of immunovirotherapy for gliomas.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- CRISPR/Cas9 Screening Reveals that UBE2L3 Modulates Autophagic Flux through TSC2 Ubiquitination and Potentiates PD-1 Blockade in Triple-Negative Breast Cancer.
- Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.
- Comparative effectiveness of first-line anti-PD-1 versus cetuximab in advanced cutaneous squamous cell carcinoma: A nationwide population-based study using the French national health data system.
- Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study.